Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
Why now
Thesis: Early-stage trial, no near-term revenue impact
Catalyst to watch: Interim efficacy or safety readout
Main risk: Head-to-head trial may fail versus nivolumab
Why it matters
A global Phase III head-to-head oncology trial is a clinical milestone but years from commercial readout.
Details
HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4...
Sources
- prnewswire · 2026-09-28 02:05 UTC